ASMB
NEUTRAL
$28.11
Live
Assembly Biosciences, Inc. · NASDAQ
Target $47.75
(+69.8%)
$7.75
52W Range
$39.71
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$444.7M
P/E
N/A
ROE
-36.9%
Profit margin
-103.6%
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
72%
ASMB's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the company exhibits strong revenue growth (57.6% YoY) and improving earnings surprises in recent quarters, suggesting potential operational turnaround. However, negative profitability metrics—such as a -103.65% profit margin and negative ROE—highlight persistent losses. The stock trades at a premium valuation (Price/Sales of 11.96) with no dividend, reflecting high growth expectations rather than intrinsic value. Analysts maintain a target price of $47.75, implying upside, but consensus is weak with only four analysts.
Key Strengths
Strong revenue growth of 57.6% YoY, indicating market traction
Improving earnings surprise trend in the last four quarters (average +12.52%)
Significant recent EPS improvement: +52.3% YoY and +45.9% Q/Q
Low debt-to-equity ratio (0.02) and strong liquidity (Current Ratio: 4.44)
Positive insider sentiment (40/100), suggesting some confidence in management
Key Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profitability across all margins and ROE/ROA, indicating unsustainable losses
No Graham Number or intrinsic value estimate, reflecting lack of stable earnings
High Price/Sales ratio (11.96) suggests overvaluation relative to fundamentals
Absence of analyst consensus (no target mean/median) and low coverage (4 analysts)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
29
Weak
30
65
35
15
0
AI Verdict
Neutral
Key drivers: Strong revenue growth and improving earnings surprises, Severe financial health issues (Piotroski F-Score: 0), High valuation multiples without earnings support, Lack of profitability and negative ROE/ROA
Confidence
75%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- High revenue growth may justify premium valuation in growth-oriented sectors
Watchpoints
- No Graham Number or intrinsic value due to negative earnings
- Price/Sales of 11.96 is extremely high for a pre-profit company
- No dividend or cash flow to support valuation
Future
65/100
Ref Growth rates
Positives
- 57.6% YoY revenue growth and improving EPS trends
- Recent quarters show consistent earnings beat rates (3/4 in last 4)
- Significant EPS improvement: +52.3% YoY and +45.9% Q/Q
Watchpoints
- No forward P/E or PEG available due to negative earnings
- High growth expectations may not be sustainable without profitability
Past
35/100
Ref Historical trends
Positives
- Historical earnings surprises show volatility but recent improvement
- Significant EPS recovery from deep losses in 2020–2022
Watchpoints
- Persistent negative margins and ROE over multiple years
- Large negative surprises in 2020–2023 indicate poor execution
- Profitability has not stabilized despite revenue growth
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Extremely low debt-to-equity (0.02) and high liquidity (Current Ratio: 4.44)
- No debt obligations to service
Watchpoints
- Piotroski F-Score of 0/9 indicates complete failure on financial health criteria
- No Altman Z-Score available, but low score implies distress risk
- Negative ROE (-36.94%), ROA (-15.96%), and negative cash flow indicators
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength: 0/100, indicating no dividend policy
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$28.11
Analyst Target
$47.75
Upside/Downside
+69.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ASMB and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ASMB
Assembly Biosciences, Inc.
Primary
|
-54.7% | +80.2% | +165.0% | +28.7% | +2.8% | -0.6% |
|
PRTC
PureTech Health plc
Peer
|
-68.3% | -33.5% | +9.3% | +1.7% | +12.6% | +10.9% |
|
ALT
Altimmune, Inc.
Peer
|
-80.3% | -68.4% | -32.7% | -3.9% | -24.4% | -1.1% |
|
XOMA
XOMA Royalty Corporation
Peer
|
+0.5% | +108.7% | +62.3% | +10.6% | +29.7% | -4.3% |
|
MYGN
Myriad Genetics, Inc.
Peer
|
-82.9% | -78.0% | -39.2% | -37.0% | +7.0% | +3.6% |
ASM
Assembly Biosciences, Inc.
Primary
5Y
-54.7%
3Y
+80.2%
1Y
+165.0%
6M
+28.7%
1M
+2.8%
1W
-0.6%
PRT
PureTech Health plc
Peer
5Y
-68.3%
3Y
-33.5%
1Y
+9.3%
6M
+1.7%
1M
+12.6%
1W
+10.9%
ALT
Altimmune, Inc.
Peer
5Y
-80.3%
3Y
-68.4%
1Y
-32.7%
6M
-3.9%
1M
-24.4%
1W
-1.1%
XOM
XOMA Royalty Corporation
Peer
5Y
+0.5%
3Y
+108.7%
1Y
+62.3%
6M
+10.6%
1M
+29.7%
1W
-4.3%
MYG
Myriad Genetics, Inc.
Peer
5Y
-82.9%
3Y
-78.0%
1Y
-39.2%
6M
-37.0%
1M
+7.0%
1W
+3.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-8.03
PEG Ratio
N/A
P/B Ratio
2.43
P/S Ratio
11.96
EV/Revenue
5.78
EV/EBITDA
-4.96
Market Cap
$444.7M
Profitability
Profit margins and return metrics
Profit Margin
-103.65%
Operating Margin
-100.87%
Gross Margin
-66.29%
ROE
-36.94%
ROA
-15.96%
Growth
Revenue and earnings growth rates
Revenue Growth
+57.6%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
4.44
Strong
Quick Ratio
4.39
Excellent
Cash/Share
$14.7
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Op. Margin
-100.9%
Net Margin
-85.2%
Total Assets
$0.2B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.31x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-10
$-0.72
-10.2% surprise
2025-08-06
$-1.33
+23.1% surprise
2025-05-08
$-1.17
+26.9% surprise
2025-03-20
$-1.57
+10.3% surprise
Healthcare Sector Comparison
Comparing ASMB against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-36.94%
This Stock
vs
-88.14%
Sector Avg
-58.1%
(Below Avg)
Profit Margin
-103.65%
This Stock
vs
-16.28%
Sector Avg
+536.6%
(Superior)
Debt to Equity
0.02
This Stock
vs
2.66
Sector Avg
-99.4%
(Less Debt)
Revenue Growth
57.6%
This Stock
vs
124.04%
Sector Avg
-53.6%
(Slower)
Current Ratio
4.44
This Stock
vs
4.47
Sector Avg
-0.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ASMB
Assembly Biosciences, Inc.
|
NEUTRAL | $444.7M | - | -36.9% | -103.6% | $28.11 | |
|
PRTC
PureTech Health plc
|
NEUTRAL | $445.46M | 10.7 | 9.4% | 793.0% | $18.3 | Compare |
|
ALT
Altimmune, Inc.
|
BEARISH | $438.31M | - | -50.6% | -% | $3.5 | Compare |
|
XOMA
XOMA Royalty Corporation
|
NEUTRAL | $451.49M | 25.95 | 34.1% | 60.8% | $37.89 | Compare |
|
MYGN
Myriad Genetics, Inc.
|
BEARISH | $459.13M | - | -23.5% | -41.3% | $4.91 | Compare |
ASMB
Assembly...
NEUTRAL
Mkt Cap
$445M
P/E
-
ROE
-36.9%
Price
$28.11
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
4 analysts
HC Wainwright & Co.
2025-12-22
Buy
Buy
Mizuho
2025-11-20
Outperform
Outperform
HC Wainwright & Co.
2025-10-14
Buy
Buy
JMP Securities
2025-09-24
Market Outperform
Past News Coverage
Recent headlines mentioning ASMB from our newsroom.
Newest → oldest
No matching news yet.